Alpha Tau to Participate in May Investor Conferences
Alpha Tau to Participate in May Investor Conferences
JERUSALEM, May 01, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, today announced that CFO Raphi Levy will present at the following investor conferences in May 2024.
耶路撒冷，2024年5月1日（環球通訊社）——創新型α放射癌症療法Alpha Dart的開發商Alpha Tau Medical Ltd.（“Alpha Tau” 或 “公司”）（納斯達克股票代碼：DRTS，DRTSW）今天宣佈，首席財務官拉菲·利維將於2024年5月出席以下投資者會議。
| Event: | Guggenheim Securities Radiopharmaceuticals Day |
| Format: | Presentation |
| Date: | May 13, 2024 |
| Time: | 11:30AM ET |
| Location: | New York, NY |
| 活動： | 古根海姆證券放射性藥物日 |
| 格式： | 演示 |
| 日期： | 2024年5月13日 |
| 時間： | 美國東部時間上午 11:30 |
| 地點： | 紐約，紐約 |
| Event: | H.C. Wainwright 2ndAnnual BioConnect Investor Conference |
| Format: | Fireside Chat |
| Date: | May 20, 2024 |
| Time: | 2PM ET |
| Location: | New York, NY |
| 活動： | H.C. Wainwright 2和年度BioConnect投資者大會 |
| 格式： | 爐邊聊天 |
| 日期： | 2024年5月20日 |
| 時間： | 東部時間下午 2 點 |
| 地點： | 紐約，紐約 |
Mr. Levy will also be available for 1x1 investor meetings at the conferences. Please reach out to your Guggenheim Securities and H.C. Wainwright representatives to schedule.
利維先生還將出席會議期間的1x1投資者會議。請聯繫您的古根海姆證券和H.C. Wainwright代表安排時間。
About Alpha Tau Medical Ltd.
關於 Alpha Tau 醫療有限公司
Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
Alpha Tau成立於2016年，是一家以色列醫療器械公司，專注於實體瘤治療的Alpha Dart的研究、開發和潛在商業化。該技術最初由特拉維夫大學的伊扎克·凱爾森教授和尤娜·凱薩里教授開發。
About Alpha DaRT
關於 Alpha Dart
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Alpha dART（彌散型α-發射器放射療法）旨在通過在腫瘤內輸送浸過的鐳-224放射源，對實體瘤進行高效、隨形的α射線照射。當鐳衰變時，其短壽命的女兒會從源頭釋放並分散，同時發射出高能量的α粒子，目的是摧毀腫瘤。由於發射α的原子只能在很短的距離內擴散，因此Alpha Dart的目標是主要影響腫瘤，並保護腫瘤周圍的健康組織。
Investor Relations Contact:
投資者關係聯繫人：
IR@alphatau.com
IR@alphatau.com
譯文內容由第三人軟體翻譯。